Stratos Wealth Advisors LLC Has $538,000 Position in Boston Scientific Co. (NYSE:BSX)

Stratos Wealth Advisors LLC grew its holdings in Boston Scientific Co. (NYSE:BSX) by 8.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,419 shares of the medical equipment provider’s stock after purchasing an additional 522 shares during the quarter. Stratos Wealth Advisors LLC’s holdings in Boston Scientific were worth $538,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Aaron Wealth Advisors LLC lifted its stake in Boston Scientific by 26.1% in the third quarter. Aaron Wealth Advisors LLC now owns 8,685 shares of the medical equipment provider’s stock valued at $728,000 after buying an additional 1,799 shares during the period. Stonegate Investment Group LLC boosted its stake in Boston Scientific by 7.5% during the third quarter. Stonegate Investment Group LLC now owns 7,701 shares of the medical equipment provider’s stock worth $645,000 after acquiring an additional 534 shares in the last quarter. V Square Quantitative Management LLC grew its holdings in Boston Scientific by 20.8% in the third quarter. V Square Quantitative Management LLC now owns 11,133 shares of the medical equipment provider’s stock worth $933,000 after purchasing an additional 1,914 shares during the period. CHB Investment Group LLC bought a new stake in Boston Scientific in the third quarter valued at $2,900,000. Finally, Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Boston Scientific by 2.0% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 172,494 shares of the medical equipment provider’s stock valued at $14,455,000 after purchasing an additional 3,433 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX opened at $88.05 on Tuesday. Boston Scientific Co. has a fifty-two week low of $49.15 and a fifty-two week high of $88.79. The firm has a 50-day moving average of $82.73 and a 200 day moving average of $77.37. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The firm has a market cap of $129.18 billion, a P/E ratio of 73.99, a PEG ratio of 2.87 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. The firm had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The company’s revenue was up 14.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.53 EPS. On average, research analysts expect that Boston Scientific Co. will post 2.4 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently commented on BSX shares. Citigroup raised their target price on Boston Scientific from $90.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Needham & Company LLC downgraded Boston Scientific from a “buy” rating to a “hold” rating and set a $86.00 price objective for the company. in a report on Friday. Deutsche Bank Aktiengesellschaft increased their target price on Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a report on Thursday, July 25th. Raymond James boosted their price target on shares of Boston Scientific from $91.00 to $94.00 and gave the company a “strong-buy” rating in a research note on Wednesday, September 4th. Finally, Robert W. Baird raised their price objective on shares of Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $90.24.

Insiders Place Their Bets

In other news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the transaction, the executive vice president now owns 160,467 shares in the company, valued at approximately $13,639,695. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the sale, the executive vice president now directly owns 160,467 shares in the company, valued at approximately $13,639,695. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the transaction, the chief executive officer now owns 1,572,096 shares of the company’s stock, valued at $133,046,484.48. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 316,253 shares of company stock valued at $26,714,298 over the last ninety days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.